

IBS-D: The Role of Pathophysiology in Assessment and Treatment

Jeffrey B. Danzig, MD

REFERENCES

American College of Gastroenterology Task Force on IBS. An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome. *Am J Gastroenterol*. 2009;104(suppl 1):S1-S35. <http://acggi.net/wp-content/uploads/2011/07/media-releases-ajg2008122a.pdf>

American Gastroenterological Association. IBS in America: Survey Summary Findings. December 2015. <http://www.multivu.com/players/English/7634451-aga-ibs-in-america-survey/docs/survey-findings-pdf-635473172.pdf>

Björkman I, Simrén M, Ringström G, Jakobsson Ung E. Patients' experiences of healthcare encounters in severe irritable bowel syndrome: an analysis based on narrative and feminist theory. *J Clin Nurs*. 2016;25(19-20):2967-2978. <https://www.ncbi.nlm.nih.gov/pubmed/27218818>

Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. *Health Qual Life Outcomes*. 2017; 15(1):35. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310011/>

Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. *Am J Gastroenterol*. 2001;96(5):1499-1506. <https://www.ncbi.nlm.nih.gov/pubmed/11374689>

Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. *JAMA*. 2015; 313(9): 949-958. <https://www.ncbi.nlm.nih.gov/pubmed/25734736>

Cook IJ, van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. *Gastroenterology*. 1987;93(4):727-733. <https://www.ncbi.nlm.nih.gov/pubmed/3623019>


Dhaliwal SK, Hunt RH. Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective. *Eur J Gastroenterol Hepatol*. 2004;16(11):1161-1166. <https://www.ncbi.nlm.nih.gov/pubmed/15489576>

Di Palma JA, Herrera JL. The role of effective clinician-patient communication in the management of irritable bowel syndrome and chronic constipation. *J Clin Gastroenterol*. 2012;46(9):748-751. <https://www.ncbi.nlm.nih.gov/pubmed/22810107>

Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. *Gastroenterology*. 2002;123(6):2108-2131. [https://www.gastrojournal.org/article/S0016-5085\(02\)00481-X/fulltext](https://www.gastrojournal.org/article/S0016-5085(02)00481-X/fulltext)

Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotrophic hormone in normal controls and patients with irritable bowel syndrome. *Gut*. 1998;42(6):845-849. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1727153/pdf/v042p00845.pdf>

Good L, Rosario R, Panas R. New therapeutic option for irritable bowel syndrome: serum-derived bovine immunoglobulin. *World J Gastroenterol*. 2015;21(11):3361-3366. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363768/>



IBS-D: The Role of Pathophysiology in Assessment and Treatment

Jeffrey B. Danzig, MD

REFERENCES (cont'd)

Håkanson C, Sahlbeg-Blom E, Ternestadt BM. Being in the patient position: experiences of health care among people with irritable bowel syndrome. *Qual Health Res*. 2010;20(8):1116-1127. <https://www.ncbi.nlm.nih.gov/pubmed/20463359>

Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. *Gastroenterology*. 2014;146(1):67-75.e5. [https://www.gastrojournal.org/article/S0016-5085\(13\)01407-8/fulltext?referrer=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2F](https://www.gastrojournal.org/article/S0016-5085(13)01407-8/fulltext?referrer=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2F)

Halpert A, Dalton CB, Palsson O, et al. Irritable bowel syndrome patients' ideal expectations and recent experiences with healthcare providers: a national survey. *Dig Dis Sci*. 2010;55(2):375-383. <https://www.ncbi.nlm.nih.gov/pubmed/19513835>

Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. *Lancet Gastroenterol Hepatol*. 2016;1(2):133-146. [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(16\)30023-1/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(16)30023-1/fulltext)

Hungin APS, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. *Aliment Pharmacol Ther*. 2005;21(11):1365-1375. <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2005.02463.x>

Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? *World J Gastroenterol*. 2014;20(39):14105-14125. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202342/>

Kumar D, Wingate DL. The irritable bowel syndrome: a paroxysmal motor disorder. *Lancet*. 1985; 2(8462):973-977. <https://www.ncbi.nlm.nih.gov/pubmed/2865504>


Lacy BE, Mearin F, Chang L, et al. Bowel disorders. *Gastroenterology*. 2016;150(6):1393-1407.e5. [https://www.gastrojournal.org/article/S0016-5085\(16\)00222-5/abstract](https://www.gastrojournal.org/article/S0016-5085(16)00222-5/abstract)

Lacy BE, Moreau JC. Diarrhea-predominant irritable bowel syndrome: diagnosis, etiology, and new treatment considerations. *J Am Assoc Nurse Pract*. 2016;28(7):393-404. <https://www.ncbi.nlm.nih.gov/pubmed/27436200>

Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. *Clin Gastroenterol Hepatol*. 2012;10(7):712-721.e4. [https://www.cghjournal.org/article/S1542-3565\(12\)00308-4/fulltext](https://www.cghjournal.org/article/S1542-3565(12)00308-4/fulltext)

Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. *Am J Gastroenterol*. 2015;110(3):444-454. <https://www.ncbi.nlm.nih.gov/pubmed/25732419>

Petschow BW, Burnett B, Shaw AL, et al. Serum-derived bovine immunoglobulin/protein isolate: postulated mechanism of action for management of enteropathy. *Clin Exp Gastroenterol*. 2014; 7:181-190. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041178/>



IBS-D: The Role of Pathophysiology in Assessment and Treatment

Jeffrey B. Danzig, MD

REFERENCES (cont'd)

- Pimentel M, Lembo A, Chey WD, et al; for the TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. *N Engl J Med*. 2011;364(1):22-32. <https://www.nejm.org/doi/full/10.1056/NEJMoa1004409>
- Pimentel M, Purdy C, Magar R, Rezaie A. A predictive model to estimate cost savings of a novel diagnostic blood panel for diagnosis of diarrhea-predominant irritable bowel syndrome. *Clin Ther*. 2016;38(7):1638-1652.e9. [https://www.clinicaltherapeutics.com/article/S0149-2918\(16\)30309-5/fulltext](https://www.clinicaltherapeutics.com/article/S0149-2918(16)30309-5/fulltext)
- Riedl A, Maass J, Fliege H, et al. Subjective theories of illness and clinical and psychological outcomes in patients with irritable bowel syndrome. *J Psychosom Res*. 2009;67(5):449-455. [https://www.jpsychores.com/article/S0022-3999\(09\)00040-3/abstract](https://www.jpsychores.com/article/S0022-3999(09)00040-3/abstract)
- Rodriguez-Fandiño O, Hernández-Ruiz J, Schmulson M. From cytokines to toll-like receptors and beyond – current knowledge and future research needs in irritable bowel syndrome. *J Neurogastroenterol Motil*. 2010;16(4):363-373. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978389/>
- Saito YA, Petersen GM, Locke GR 3rd, Talley NJ. The genetics of irritable bowel syndrome. *Clin Gastroenterol Hepatol*. 2005;3(11):1057-1065. <https://www.ncbi.nlm.nih.gov/pubmed/16271334>
- Sayuk GS, Wolf R, Chang L. Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. *Am J Gastroenterol*. 2017;112(6):892-899. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465427/>
- Solmaz M, Kavuk I, Sayar K. Psychological factors in irritable bowel syndrome. *Eur J Med Res*. 2003; 8(12):549-556. <http://europemc.org/abstract/MED/14711602>
- Talley NJ, Fodor AA. Bugs, stool, and the irritable bowel syndrome: too much is as bad as too little? *Gastroenterol*. 2011;141(5):1555-1559. <https://www.ncbi.nlm.nih.gov/pubmed/21945058>
- Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. *Gastroenterology*. 1990;98(5 Pt 1):1187-1192. <https://www.ncbi.nlm.nih.gov/pubmed/2323511>
- Wilson D, Evans M, Weaver E, et al. Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. *Clin Med Insights Gastroenterol*. 2013;6:49-60. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020402/>
- Zhuang X, Xiong L, Li L, Li M, Chen M. Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis. *J Gastroenterol Hepatol*. 2017;32(1):28-38. <https://www.ncbi.nlm.nih.gov/pubmed/27300149>